Eleven Biotherapeutics Company Profile (NASDAQ:EBIO)

About Eleven Biotherapeutics

Eleven Biotherapeutics logoEleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company's product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company's therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EBIO
  • CUSIP:
Key Metrics:
  • Previous Close: $2.08
  • 50 Day Moving Average: $2.15
  • 200 Day Moving Average: $2.80
  • 52-Week Range: $0.28 - $5.97
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.12
  • P/E Growth: 0.00
  • Market Cap: $32.02M
  • Outstanding Shares: 15,393,000
  • Beta: 3.69
Profitability:
  • Net Margins: -16.51%
  • Return on Equity: -25.00%
  • Return on Assets: -14.02%
Debt:
  • Current Ratio: 5.08%
  • Quick Ratio: 5.08%
Additional Links:
Companies Related to Eleven Biotherapeutics:

Analyst Ratings

Consensus Ratings for Eleven Biotherapeutics (NASDAQ:EBIO) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Eleven Biotherapeutics (NASDAQ:EBIO)
Show:
DateFirmActionRatingPrice TargetDetails
1/19/2016Citigroup Inc.DowngradeBuy -> NeutralView Rating Details
1/18/2016Leerink SwannDowngradeOutperform -> Market PerformView Rating Details
(Data available from 2/21/2015 forward)

Earnings

Earnings History for Eleven Biotherapeutics (NASDAQ:EBIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/22/2017        
11/14/2016Q3($0.17)$0.91$28.70 millionViewListenView Earnings Details
8/12/2016Q2($0.33)ViewN/AView Earnings Details
3/24/2016Q4($0.32)($0.53)ViewN/AView Earnings Details
11/4/2015Q315($0.33)($0.50)ViewListenView Earnings Details
8/13/2015Q215($0.43)($0.36)ViewListenView Earnings Details
4/30/2015Q115($0.57)($0.36)ViewListenView Earnings Details
3/4/2015Q414($0.33)($0.49)$375.00 millionViewListenView Earnings Details
11/13/2014Q314($0.44)($0.66)ViewN/AView Earnings Details
8/13/2014($0.47)($0.51)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eleven Biotherapeutics (NASDAQ:EBIO)
Current Year EPS Consensus Estimate: $-1.75 EPS
Next Year EPS Consensus Estimate: $-1.85 EPS

Dividends

Dividend History for Eleven Biotherapeutics (NASDAQ:EBIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Eleven Biotherapeutics (NASDAQ:EBIO)
Insider Ownership Percentage: 28.70%
Institutional Ownership Percentage: 24.75%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/28/2016Abbie CelnikerDirectorSell10,031$3.00$30,093.00View SEC Filing  
9/23/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell443,422$3.16$1,401,213.52View SEC Filing  
9/21/2016Ventures Fund Iv L.P FlagshipMajor ShareholderSell322,723$3.75$1,210,211.25View SEC Filing  
9/20/2016Ventures Fund Iv L.P FlagshipMajor ShareholderSell53,917$3.39$182,778.63View SEC Filing  
9/19/2016Ventures Fund Iv L.P FlagshipMajor ShareholderSell9,700$3.31$32,107.00View SEC Filing  
9/15/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell46,692$4.18$195,172.56View SEC Filing  
9/7/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell129,497$4.54$587,916.38View SEC Filing  
8/15/2016John J MccabeCFOSell1,170$4.80$5,616.00View SEC Filing  
6/27/2016Abbie CelnikerCEOSell10,029$2.08$20,860.32View SEC Filing  
6/27/2016Karen L TubridyInsiderSell4,372$2.08$9,093.76View SEC Filing  
6/13/2016Boxer Capital, LlcMajor ShareholderSell1,042,000$2.74$2,855,080.00View SEC Filing  
2/16/2016John J MccabeSVPSell1,501$0.27$405.27View SEC Filing  
12/28/2015Abbie CelnikerCEOSell10,155$2.85$28,941.75View SEC Filing  
12/28/2015Eric Steven FurfineInsiderSell4,652$2.85$13,258.20View SEC Filing  
5/8/2015Jafco Super V3 Investment LimiMajor ShareholderSell33,400$13.23$441,882.00View SEC Filing  
2/2/2015Jafco Super V3 Investment LimiMajor ShareholderSell17,900$11.62$207,998.00View SEC Filing  
1/30/2015Jafco Super V3 Investment LimiMajor ShareholderSell120,000$11.62$1,394,400.00View SEC Filing  
1/26/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,300$11.85$74,655.00View SEC Filing  
1/22/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,300$11.82$74,466.00View SEC Filing  
1/16/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,100$12.07$73,627.00View SEC Filing  
8/26/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,000$11.54$23,080.00View SEC Filing  
8/20/2014Jafco Super V3 Investment LimiMajor ShareholderSell1,165$11.54$13,444.10View SEC Filing  
8/18/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,600$11.81$30,706.00View SEC Filing  
8/14/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,000$11.75$23,500.00View SEC Filing  
2/11/2014Jafco Super V3 Investment LimiMajor ShareholderBuy219,790$10.00$2,197,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Eleven Biotherapeutics (NASDAQ:EBIO)
DateHeadline
News IconBrokerage Firm Analysts Consensus on Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) Manhattan Associates, Inc ... - Rockville Register (NASDAQ:EBIO)
rockvilleregister.com - February 19 at 4:26 PM
seekingalpha.com logoEleven Biotherapeutics (EBIO) Presents At 19th Annual BIO CEO & Investor Conference - Slideshow (NASDAQ:EBIO)
seekingalpha.com - February 16 at 8:41 PM
seekingalpha.com logoEleven Biotherapeutics (EBIO) Presents At 19th Annual BIO CEO & Investor Conference - Slideshow (NASDAQ:EBIO)
seekingalpha.com - February 16 at 8:41 PM
News IconWhat Are the Technicals Saying About These Shares: Eleven Biotherapeutics Inc. (EBIO) - Baxter Review (NASDAQ:EBIO)
baxternewsreview.com - February 16 at 3:38 PM
4-traders.com logoRexahn Pharmaceuticals : How These Biotech Stocks are Faring? -- Agenus, Tokai Pharma, Eleven Biotherapeutics, and Rexahn Pharma (NASDAQ:EBIO)
www.4-traders.com - February 14 at 10:47 PM
News IconHow These Biotech Stocks are Faring? -- Agenus, Tokai Pharma, Eleven Biotherapeutics, and Rexahn Pharma (NASDAQ:EBIO)
www.medindia.net - February 14 at 10:47 PM
News IconInvesting Focus: Indicators in View on Shares of Eleven Biotherapeutics Inc. (EBIO) - Rives Journal (NASDAQ:EBIO)
rivesjournal.com - February 14 at 5:46 PM
prnewswire.com logoHow These Biotech Stocks are Faring? -- Agenus, Tokai Pharma, Eleven Biotherapeutics, and Rexahn Pharma - PR Newswire (press release) (NASDAQ:EBIO)
www.prnewswire.com - February 14 at 5:46 PM
News IconEleven Biotherapeutics, Inc. (EBIO) earnings reaction history in focus - Post Analyst (NASDAQ:EBIO)
postanalyst.com - February 13 at 7:18 AM
finance.yahoo.com logoEleven Biotherapeutics to Present at the 2017 BIO CEO & Investor Conference (NASDAQ:EBIO)
finance.yahoo.com - February 7 at 6:01 PM
News IconVolatile Stock Causing a Fracas Mid-Session: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Davidson Register (NASDAQ:EBIO)
davidsonregister.com - February 7 at 2:57 AM
News IconMannKind Corporation (NASDAQ:MNKD)- Profitability Analysis To Overcome Risk: Eleven Biotherapeutics (NASDAQ ... - Street Wise Report (press release) (blog) (NASDAQ:EBIO)
streetwisereport.com - February 5 at 4:45 PM
News IconTrading Radar: Zooming in on Shares of Eleven Biotherapeutics Inc. (EBIO) - Sherwood Daily (NASDAQ:EBIO)
sherwooddaily.com - February 4 at 5:00 PM
News IconTechnical Trading: Focus on Shares of Eleven Biotherapeutics Inc. (EBIO) - Sherwood Daily (NASDAQ:EBIO)
sherwooddaily.com - February 2 at 5:20 PM
News IconOn the Hunt For the Next Wonder Stock: Penny Stock Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Nelson Research (NASDAQ:EBIO)
nelsonobserver.com - February 1 at 10:25 PM
News IconChecking Indicator Levels for Eleven Biotherapeutics Inc. (EBIO) - Sherwood Daily (NASDAQ:EBIO)
sherwooddaily.com - February 1 at 10:25 PM
News IconStock Dragging Lower Heading Into The Open: Eleven ... - Aiken Advocate (NASDAQ:EBIO)
aikenadvocate.com - February 1 at 10:25 PM
News IconChart Inspection on Shares of Eleven Biotherapeutics Inc. (EBIO) - Sherwood Daily (NASDAQ:EBIO)
sherwooddaily.com - February 1 at 5:25 PM
News IconNewsworthy Wonder Stock: Penny Stock Investors Looking at Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Nelson Research (NASDAQ:EBIO)
nelsonobserver.com - February 1 at 5:25 PM
News IconNoveome Biotherapeutics, Inc. Company Profile (NASDAQ:EBIO)
www.bioportfolio.com - January 31 at 5:32 PM
News IconIs This Stock Capable of a Bull Run: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Nelson Research (NASDAQ:EBIO)
nelsonobserver.com - January 30 at 11:44 PM
News IconRSI Update on Shares of Eleven Biotherapeutics Inc. (EBIO) - Sherwood Daily (NASDAQ:EBIO)
sherwooddaily.com - January 30 at 11:44 PM
News IconIs the Needle Ready to Move on Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Prospect Journal (NASDAQ:EBIO)
prospectjournal.com - January 30 at 11:44 PM
News IconHigh Volatility Moving the Needle For Shares of Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Wall Street Beacon (NASDAQ:EBIO)
wsbeacon.com - January 30 at 11:44 PM
News IconMy Watchlist for Monday, January 30 (NASDAQ:EBIO)
ac-investor.blogspot.com - January 28 at 5:03 PM
News IconStock Momentum in Focus on Shares of Eleven Biotherapeutics Inc. (EBIO) - Sherwood Daily (NASDAQ:EBIO)
sherwooddaily.com - January 27 at 6:30 PM
News IconAre There Any Catalysts to Propel This Stock Forward: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Prospect Journal (NASDAQ:EBIO)
prospectjournal.com - January 26 at 6:08 PM
News IconMarket Rover: Looking at Levels on Shares of Eleven Biotherapeutics Inc. (EBIO) - Sherwood Daily (NASDAQ:EBIO)
sherwooddaily.com - January 26 at 6:08 PM
News IconEleven Biotherapeutics Inc (EBIO) Valuation According To Analysts - UK Market News (NASDAQ:EBIO)
www.ukmarketnews.co.uk - January 24 at 10:32 PM
News IconTicker Watch: Technical Views on Shares of Eleven Biotherapeutics Inc. (EBIO) - Sherwood Daily (NASDAQ:EBIO)
sherwooddaily.com - January 24 at 10:32 PM
News IconShare Focus: Checking the Indicators on Eleven Biotherapeutics Inc. (EBIO) - Sherwood Daily (NASDAQ:EBIO)
sherwooddaily.com - January 18 at 10:16 PM
News IconNear-Term, Can This Stock Move the Needle: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Prospect Journal (NASDAQ:EBIO)
prospectjournal.com - January 18 at 10:16 PM
News IconEquity Insight: Indicator Review for Eleven Biotherapeutics Inc. (EBIO) - Sherwood Daily (NASDAQ:EBIO)
sherwooddaily.com - January 17 at 5:43 PM
News IconIs the Needle Ready to Move for Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Prospect Journal (NASDAQ:EBIO)
prospectjournal.com - January 17 at 5:43 PM
News IconCheap Stock, But is it a Bargain: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Prospect Journal (NASDAQ:EBIO)
prospectjournal.com - January 17 at 8:11 AM
News IconShares Skittish Ahead of The Bell: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Wall Street Beacon (NASDAQ:EBIO)
wsbeacon.com - January 13 at 11:08 PM
News IconBargain Hunter Investor Update on Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Prospect Journal (NASDAQ:EBIO)
prospectjournal.com - January 13 at 11:08 PM
News IconAre Institutions Jumping Ship on Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Wall Street Beacon (NASDAQ:EBIO)
wsbeacon.com - January 12 at 3:27 AM
News IconEleven Biotherapeutics, Inc. (NASDAQ:EBIO) Insider Ownership stands at 3.4 - The Newburgh Press (NASDAQ:EBIO)
newburghpress.com - January 11 at 5:24 PM
News IconStock Getting Tripped Up In Session: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Wall Street Beacon (NASDAQ:EBIO)
wsbeacon.com - January 11 at 5:24 PM
News IconWhich Direction is This Stock Headed? Update on Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Prospect Journal (NASDAQ:EBIO)
prospectjournal.com - January 11 at 5:24 PM
News IconStock Reaching Most Volatile List Today: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Wall Street Beacon (NASDAQ:EBIO)
wsbeacon.com - January 11 at 5:24 PM
News IconEleven Biotherapeutics, Inc. (NASDAQ:EBIO) Closed the Last Trading Session with increase of 6.48% - The Newburgh Press (NASDAQ:EBIO)
newburghpress.com - January 10 at 10:50 PM
biz.yahoo.com logoELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events (NASDAQ:EBIO)
biz.yahoo.com - January 6 at 5:23 PM
News IconA Look at this Riveting Stock: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Prospect Journal (NASDAQ:EBIO)
prospectjournal.com - January 3 at 6:45 PM
prnewswire.com logoBiotech Stocks on Investors' Radar -- Eleven Biotherapeutics, Illumina, Sangamo Biosciences, and CytRx - PR Newswire (press release) (NASDAQ:EBIO)
www.prnewswire.com - December 29 at 3:45 PM
News IconIs This Equity Ready for a Breakout: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Prospect Journal (NASDAQ:EBIO)
prospectjournal.com - December 29 at 3:45 PM
News IconPrimed for Breakout or Bust? A look at Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Prospect Journal (NASDAQ:EBIO)
prospectjournal.com - December 21 at 10:13 AM
News IconCan This Stock Gain Traction: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - Prospect Journal (NASDAQ:EBIO)
prospectjournal.com - December 20 at 9:55 AM
biz.yahoo.com logoELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Stat (NASDAQ:EBIO)
biz.yahoo.com - December 6 at 5:03 PM

Social

What is Eleven Biotherapeutics' stock symbol?

Eleven Biotherapeutics trades on the NASDAQ under the ticker symbol "EBIO."

When will Eleven Biotherapeutics announce their earnings?

Eleven Biotherapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 22nd 2017.

Who owns Eleven Biotherapeutics stock?

Eleven Biotherapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Oxford Asset Management (1.17%). Company insiders that own Eleven Biotherapeutics stock include Abbie Celniker, Boxer Capital, Llc, Eric Steven Furfine, Jafco Super V3 Investment Limi, John J Mccabe, Karen L Tubridy, Ventures Fund 2007 L Flagship and Ventures Fund Iv LP Flagship.

Who bought Eleven Biotherapeutics stock? Who is buying Eleven Biotherapeutics stock?

Eleven Biotherapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Oxford Asset Management.

How do I buy Eleven Biotherapeutics stock?

Shares of Eleven Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Eleven Biotherapeutics stock cost?

One share of Eleven Biotherapeutics stock can currently be purchased for approximately $2.08.

Eleven Biotherapeutics (NASDAQ:EBIO) Chart for Tuesday, February, 21, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)

Earnings History Chart

Earnings by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)

Dividend History Chart

Dividend Payments by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)

Last Updated on 2/21/2017 by MarketBeat.com Staff